Povetacicept, a human TACI–Fc fusion protein engineered for dual APRIL/BAFF inhibition, has been studied in patients with IgAN, primary membranous nephropathy (MN), and lupus nephritis. The gene discussed is TNFSF13; the disease is lupus nephritis.